Eyepoint Pharmaceuticals Stock Today
| EYPT Stock | USD 19.74 0.20 1.00% |
Performance0 of 100
| Odds Of DistressLess than 45
|
Eyepoint Pharmaceuticals is selling for under 19.74 as of the 4th of May 2024; that is -1 percent decrease since the beginning of the trading day. The stock's last reported lowest price was 17.83. Eyepoint Pharmaceuticals has 45 percent odds of going through some form of financial distress in the next two years and has generated negative returns to investors over the last 90 days. Equity ratings for Eyepoint Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 4th of April 2024 and ending today, the 4th of May 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of January 2005 | Category Healthcare | Classification Health Care |
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. The company has 52.08 M outstanding shares of which 6.54 M shares are currently shorted by private and institutional investors with about 9.02 trading days to cover. More on Eyepoint Pharmaceuticals
Moving together with Eyepoint Stock
| 0.71 | IRNRF | Iron Road Limited | PairCorr |
Moving against Eyepoint Stock
| 0.91 | XOM | Exxon Mobil Corp Sell-off Trend | PairCorr |
| 0.9 | BAC | Bank of America Financial Report 16th of July 2024 | PairCorr |
| 0.87 | AA | Alcoa Corp Financial Report 17th of July 2024 | PairCorr |
| 0.84 | AXP | American Express Financial Report 19th of July 2024 | PairCorr |
| 0.83 | CVX | Chevron Corp Sell-off Trend | PairCorr |
| 0.78 | DD | Dupont De Nemours Sell-off Trend | PairCorr |
| 0.76 | LRDG | Lord Global Corp | PairCorr |
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
Eyepoint Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Eyepoint Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Eyepoint Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| CEO | Nancy Lurker | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Idea | Measuring and Control Equipment (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, Measuring and Control Equipment, Health Care, Pharmaceuticals, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation Analysts covering Eyepoint Pharmaceuticals report their recommendations after researching Eyepoint Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Eyepoint Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Eyepoint Pharmaceuticals. The Eyepoint consensus assessment is calculated by taking the average forecast from all of the analysts covering Eyepoint Pharmaceuticals. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Financial Strength Based on the key indicators related to Eyepoint Pharmaceuticals' liquidity, profitability, solvency, and operating efficiency, Eyepoint Pharmaceuticals is not in a good financial situation at this time. It has a very high probability of going through financial hardship in June. Financial strength of Eyepoint Pharmaceuticals is based on its profitability, leverage, liquidity, source of funds, and operating efficiency.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eyepoint Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Eyepoint Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Eyepoint Pharmaceuticals' financial leverage. It provides some insight into what part of Eyepoint Pharmaceuticals' total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Eyepoint Pharmaceuticals (EYPT) is traded on NASDAQ Exchange in USA. It is located in 480 Pleasant Street, Watertown, MA, United States, 02472 and employs 121 people. Eyepoint Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.04 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Eyepoint Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Eyepoint Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Eyepoint Pharmaceuticals conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 52.08 M outstanding shares of which 6.54 M shares are currently shorted by private and institutional investors with about 9.02 trading days to cover.
Eyepoint Pharmaceuticals currently holds about 171.17 M in cash with 1.88 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.02.
Check Eyepoint Pharmaceuticals Probability Of Bankruptcy
Ownership AllocationEyepoint Pharmaceuticals retains a total of 52.08 Million outstanding shares. The majority of Eyepoint Pharmaceuticals outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to obtain positions in Eyepoint Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Eyepoint Pharmaceuticals. Please pay attention to any change in the institutional holdings of Eyepoint Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Eyepoint Ownership Details
Eyepoint Stock Price Odds Analysis
Attributed to a normal probability distribution, the odds of Eyepoint Pharmaceuticals jumping above the current price in 90 days from now is about 82.01%. The Eyepoint Pharmaceuticals probability density function shows the probability of Eyepoint Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days the stock has a beta coefficient of 1.7212 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Eyepoint Pharmaceuticals will likely underperform. Additionally, eyepoint Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the NYSE Composite.
Based on a normal probability distribution, the odds of Eyepoint Pharmaceuticals to move above the current price in 90 days from now is about 82.01 (This Eyepoint Pharmaceuticals probability density function shows the probability of Eyepoint Stock to fall within a particular range of prices over 90 days) .
Eyepoint Stock Institutional Holders
Institutional Holdings refers to the ownership stake in Eyepoint Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eyepoint Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eyepoint Pharmaceuticals' value.| Instituion | Recorded On | Shares | |
| Goldman Sachs Group Inc | 2023-12-31 | 1.1 M | |
| Millennium Management Llc | 2023-12-31 | 1.1 M | |
| Jennison Associates Llc | 2023-12-31 | 1.1 M | |
| Citadel Advisors Llc | 2023-09-30 | 1.1 M | |
| Deutsche Bank Ag | 2023-12-31 | 770.5 K | |
| Geode Capital Management, Llc | 2023-12-31 | 682.4 K | |
| Federated Hermes Inc | 2023-12-31 | 674.8 K | |
| Perceptive Advisors Llc | 2023-12-31 | 589.6 K | |
| Ubs Group Ag | 2023-12-31 | 574.2 K | |
| Cormorant Asset Management, Llc | 2023-12-31 | 6 M | |
| Franklin Resources Inc | 2023-12-31 | 4.6 M |
Eyepoint Pharmaceuticals Historical Income Statement
Eyepoint Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Eyepoint's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Eyepoint Pharmaceuticals revenue and expense. Eyepoint Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At this time, Eyepoint Pharmaceuticals' Selling General Administrative is comparatively stable compared to the past year. Selling And Marketing Expenses is likely to gain to about 17 M in 2024, despite the fact that EBIT is likely to grow to (70 M). View More FundamentalsEyepoint Stock Against Markets
Picking the right benchmark for Eyepoint Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Eyepoint Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Eyepoint Pharmaceuticals is critical whether you are bullish or bearish towards Eyepoint Pharmaceuticals at a given time. Please also check how Eyepoint Pharmaceuticals' historical prices are related to one of the top price index indicators.
Be your own money manager
Our tools can tell you how much better you can do entering a position in Eyepoint Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Optimization Now
Portfolio OptimizationCompute new portfolio that will generate highest expected return given your specified tolerance for risk |
| All Next | Launch Module |
Eyepoint Pharmaceuticals Corporate Directors
Eyepoint Pharmaceuticals corporate directors refer to members of an Eyepoint Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Eyepoint Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Eyepoint Pharmaceuticals' board members must vote for the resolution. The Eyepoint Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.| Douglas Godshall | Independent Director | Profile | |
| Kristine Peterson | Independent Director | Profile | |
| John Landis | Director | Profile | |
| Jay Duker | Independent Director | Profile |
How to buy Eyepoint Stock?
Before investing in Eyepoint Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Eyepoint Pharmaceuticals. To buy Eyepoint Pharmaceuticals stock, you can follow these steps:- Choose a brokerage firm: You need to select a brokerage firm to buy shares of Eyepoint Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
- Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
- Fund your account: You will need to deposit funds into your brokerage account to purchase Eyepoint Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
- Place your order: Once you have located Eyepoint Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
- Monitor your investment: After you have purchased Eyepoint Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Eyepoint Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.
Already Invested in Eyepoint Pharmaceuticals?
The danger of trading Eyepoint Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Eyepoint Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Eyepoint Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Eyepoint Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Eyepoint Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Eyepoint Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Eyepoint Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Eyepoint Pharmaceuticals Stock: Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Eyepoint Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in american community survey. For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Complementary Tools for Eyepoint Stock analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Global Correlations Find global opportunities by holding instruments from different markets |
Is Eyepoint Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyepoint Pharmaceuticals. If investors know Eyepoint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyepoint Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Revenue Per Share 1.183 | Quarterly Revenue Growth 0.332 | Return On Assets (0.17) | Return On Equity (0.39) |
The market value of Eyepoint Pharmaceuticals is measured differently than its book value, which is the value of Eyepoint that is recorded on the company's balance sheet. Investors also form their own opinion of Eyepoint Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eyepoint Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyepoint Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eyepoint Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyepoint Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyepoint Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyepoint Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.